New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed by planned BLA filing, mid-year Expecting FDA PDUFA decision and multiple...
Hence then, the article about regenxbio highlights key 2026 catalysts and announces positive long term functional outcomes in lead duchenne gene therapy program was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program )
Also on site :
- Human heads displayed at Ecuador tourist beach in warning to gangs
- Nazi salutes and drug cartels: Dutch mercenary recounts service with Kiev’s military
- Retailers Help Mitigate Risk with Oracle's AI-Driven Supply Chain Collaboration